Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy

Biochim Biophys Acta. 2015 May;1852(5):1012-9. doi: 10.1016/j.bbadis.2015.02.004. Epub 2015 Feb 19.


Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism due to the deficient activity of N-acetylgalactosamine-6-sulfate sulfatase that leads to accumulation of the keratan sulfate and chondroitin 6-sulfate in body fluids and in lysosomes. The pathophysiology of this lysosomal storage disorder is not completely understood. The aim of this study was to investigate oxidative stress parameters, pro-inflammatory cytokine and GAG levels in MPS IVA patients. We analyzed urine and blood samples from patients under ERT (n=17) and healthy age-matched controls (n=10-15). Patients presented a reduction of antioxidant defense levels, assessed by a decrease in glutathione content and by an increase in superoxide dismutase activity in erythrocytes. Concerning lipid and protein damage, it was verified increased urine isoprostanes and di-tyrosine levels and decreased plasma sulfhydryl groups in MPS IVA patients compared to controls. MPS IVA patients showed higher DNA damage than control group and this damage had an oxidative origin in both pyrimidine and purine bases. Interleukin 6 was increased in patients and presented an inverse correlation with GSH levels, showing a possible link between inflammation and oxidative stress in MPS IVA disease. The data presented suggest that pro-inflammatory and pro-oxidant states occur in MPS IVA patients even under ERT. Taking these results into account, supplementation of antioxidants in combination with ERT can be a tentative therapeutic approach with the purpose of improving the patient's quality of life. To the best of our knowledge, this is the first study relating MPS IVA patients with oxidative stress.

Keywords: Glycosaminoglycan; Inflammation; Morquio A Syndrome; Mucopolysaccharidosis type IVA; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adolescent
  • Adult
  • Blood Proteins / analysis
  • Child
  • Chondroitinsulfatases / therapeutic use*
  • Creatinine / urine
  • Cytokines / blood
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / urine
  • Enzyme Replacement Therapy / methods*
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism
  • Female
  • Glutathione / blood
  • Glycosaminoglycans / urine
  • Humans
  • Inflammation / blood
  • Inflammation / drug therapy*
  • Inflammation / urine
  • Isoprostanes / urine
  • Male
  • Mucopolysaccharidosis IV / blood
  • Mucopolysaccharidosis IV / drug therapy*
  • Mucopolysaccharidosis IV / urine
  • Oxidative Stress / drug effects*
  • Peroxidase / blood
  • Superoxide Dismutase / blood
  • Treatment Outcome
  • Tyrosine / analogs & derivatives
  • Tyrosine / urine
  • Young Adult


  • Blood Proteins
  • Cytokines
  • Glycosaminoglycans
  • Isoprostanes
  • Tyrosine
  • 8-Hydroxy-2'-Deoxyguanosine
  • Creatinine
  • dityrosine
  • Peroxidase
  • Superoxide Dismutase
  • Chondroitinsulfatases
  • GALNS protein, human
  • Deoxyguanosine
  • Glutathione